BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 30, 2002
View Archived Issues
Adenosine A2A receptor antagonists can relieve parkinsonian disability
Read More
Icos reviews second-quarter progress
Read More
Tetrahydrocannabinol is safe and effective in the treatment of agitation associated with AD
Read More
New data on donepezil presented at Alzheimer's Disease conference
Read More
Further characterization of the effects of galantamine
Read More
Vinpocetine compared to donepezil and galantamine against scopolamine-induced cognitive deficits
Read More
APC-0576 inhibits proinflammatory cytokine-induced chemokine production in human endothelial cells
Read More
Vertex presents novel JNK inhibitors for neurodegenerative diseases, etc.
Read More
Synthetic MMP inhibitor Ro-28-2653 undergoes in vitro and in vivo testing
Read More
Novel steroid 17,20 lyase inhibitors in early development at Takeda
Read More
Nippon Chemiphar researchers identify PPAR agonists with potential in obesity and other disorders
Read More
Aventis claims novel antiarrhythmic Kv1.5 channel blockers
Read More
Novel antibiotic identified in Coniochaeta ellipsoidea cultures
Read More
Researchers at Aventis report the isolation and activity of klainetins
Read More
Novel Na+/HCO3- cotransporter inhibitors described in recent patent
Read More
Clofarex enters trials in AML, ALL and solid tumors
Read More
ADVENT trial results support expanded indications for Niaspan
Read More
E.U. approval for Zavesca recommended; OGS and Actelion sign marketing agreement
Read More
Valdecoxib receives positive opinion in E.U.
Read More
Tularik sums up second-quarter achievements
Read More
SignalGene updates progress of SG-292
Read More
Final part of Aldurazyme BLA submitted, priority review requested
Read More
E.U. approval for cancer imaging agent Flucis
Read More
N20C: a selective NMDA receptor open channel blocker with a neuroprotective profile
Read More
Swedish approval for dutasteride for benign prostatic hyperplasia
Read More
